

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR REGISTRATION APPLICATION OF 神普暢™ SeQuent® Please CIS PACLITAXEL DRUG-COATED INTRACRANIAL BALLOON DILATATION CATHETER

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that 神普暢™ SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter (“**SeQuent® Please CIS**” or the “**Product**”) has recently received approval from the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) (the “**NMPA**”) for its registration application.

SeQuent® Please CIS, registered by B. Braun Medical (Suzhou) Co., Ltd. (“**B. Braun Medical**”), is an intracranial paclitaxel drug-coated balloon dilatation catheter developed based on B. Braun Medical’s mature drug-coated balloon technology. During mechanical dilatation at the target lesion, the product will release the coated paclitaxel precisely to the diseased vascular wall, which will serve as antiproliferative agents to reduce neointimal hyperplasia effectively and lower the risk of restenosis in long term. The Product is specifically designed for the anatomical characteristics of intracranial vessels, including narrow and tortuous pathways, and is intended to provide an innovative “implant-free” treatment option for intracranial vascular diseases.

Reference is made to the Company's announcement dated June 1, 2026. As disclosed therein, Shanghai Achieva Medical Suzhou Co., Ltd., a subsidiary of the Company, has obtained the exclusive distribution rights for SeQuent® Please CIS in the Chinese mainland.

The NMPA approval of SeQuent® Please CIS further expands the Group's neurointerventional product portfolio and strengthens the Group's offering in the treatment of intracranial atherosclerotic stenosis. The Group will leverage its established commercial capabilities in neurointervention to support the market introduction and commercialization of SeQuent® Please CIS in the Chinese mainland.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET THE 神普畅™ SeQuent® Please CIS PACLITAXEL DRUG-COATED INTRACRANIAL BALLOON DILATATION CATHETER SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG
Chairman and Executive Director

Hong Kong, September 25, 2026

As at the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.